Cohen R M, Ebstein R P, Daly J W, Murphy D L
J Neurosci. 1982 Nov;2(11):1588-95. doi: 10.1523/JNEUROSCI.02-11-01588.1982.
Various antidepressant drugs (monoamine oxidase inhibitors and tricyclics) enhance norepinephrine availability and lead to adaptive changes in brain noradrenergic systems, namely, decreases in the number of beta receptors and in the responsiveness of adenylate cyclase to norepinephrine monamine oxidase inhibitor, but not after 3 days, there is an increase in norepinephrine release from rat brain microsacs in response to 43 mM KCl stimulation. Microsacs prepared from 21-day clorgyline-treated animals also show a marked decrease in the inhibition of norepinephrine release caused by the alpha 2-selective agonist clonidine. These functional changes in norepinephrine release mechanisms are accompanied by a 53% reduction in brainstem alpha 2 receptor density as measured by [3H]clonidine binding. At the same time, despite findings of a decrease in beta receptor number as determined by [3H]dihydroalprenolol binding data, no significant decrease in the responses of cyclic adenosine 3': 5'-monophosphate (cyclic AMP) systems to norepinephrine stimulation is observed. Decreases in the cyclic AMP response are observed by day 35 of clorgyline treatment. The results provide direct physiological support for a change in the norepinephrine release mechanism and an effect on autoreceptors, specifically, preceding postsynaptic adaptive changes in the instance of one antidepressant, clorgyline. Difficulties in observing such changes with other antidepressants may result from the multiple nature of alpha-adrenergic receptors, especially as measured by radioactive ligand techniques; the lack of a direct relationship between physiological changes and receptors as measured by radioligand techniques; the large doses of monoamine oxidase inhibitors used in some studies; and the possible multiplicity of antidepressant molecular mechanisms.
多种抗抑郁药物(单胺氧化酶抑制剂和三环类药物)可提高去甲肾上腺素的可用性,并导致脑去甲肾上腺素能系统发生适应性变化,即β受体数量减少以及腺苷酸环化酶对去甲肾上腺素单胺氧化酶抑制剂的反应性降低,但3天后,大鼠脑微囊在43 mM KCl刺激下的去甲肾上腺素释放增加。从经21天氯吉兰治疗的动物制备的微囊也显示,α2选择性激动剂可乐定对去甲肾上腺素释放的抑制作用明显降低。去甲肾上腺素释放机制的这些功能变化伴随着通过[3H]可乐定结合测定的脑干α2受体密度降低53%。同时,尽管根据[3H]二氢阿普洛尔结合数据发现β受体数量减少,但未观察到环磷酸腺苷(cAMP)系统对去甲肾上腺素刺激的反应有明显降低。在氯吉兰治疗的第35天观察到cAMP反应降低。这些结果为去甲肾上腺素释放机制的变化以及对自身受体的影响提供了直接的生理学支持,具体而言,在一种抗抑郁药氯吉兰的情况下,突触后适应性变化之前就有这种影响。用其他抗抑郁药观察此类变化的困难可能源于α肾上腺素能受体的多重性质,特别是通过放射性配体技术测量时;放射性配体技术测量的生理变化与受体之间缺乏直接关系;一些研究中使用的大剂量单胺氧化酶抑制剂;以及抗抑郁分子机制可能的多样性。